Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
2006 (English)In: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 91, no 5, 667-670 p.Article in journal (Refereed) Published
The present study evaluated the combination of antithymocyte globulin (ATG) and cyclosporine A (CsA) in patients with low-risk myelodysplastic syndromes. Twenty patients (17 with refractory anemia and 3 with refractory anemia with excess blasts) received treatment with rabbit-ATG plus CsA. The overall response rate was 30% (6/20); three of the six responders had a complete response. The responses lasted 2-58 months, with two patients still being in complete remission at 42 and 58 months. Short-lasting cytogenetic remissions were achieved in two patients. ATG was poorly tolerated in patients over 70 years of age. Four out of 20 patients progressed to acute myeloid leukemia within a year. We conclude that immunosuppressive treatment may be a therapeutic option for selected patients with myelodysplastic syndrome.
Place, publisher, year, edition, pages
2006. Vol. 91, no 5, 667-670 p.
MDS, ATG, cyclosporine A, treatment
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-124615PubMedID: 16670072OAI: oai:DiVA.org:uu-124615DiVA: diva2:317775